Ildong Joins Oral COVID-19 Drug Race Via Shionogi Partnership
Korean Phase II/III Study To Begin Soon
Ildong has become the latest Korean pharma firm to start developing an oral COVID-19 drug in the country, potentially competing with Merck and Pfizer’s candidates which are now under approval review locally. The latest co-development deal is also set to expand the market prospects for the antiviral's Japanese originator.
You may also be interested in...
Asia Deal Watch: Astellas Looks To Next-Gen AAV Vectors Despite Gene Therapy Clinical Setbacks
Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.
Roche Exit Strengthens Pfizer And Merck & Co In Covid Pill Market
Roche has bowed out of the race to develop an oral COVID-19 therapy, leaving a lucrative but likely short-lived market for its rivals.
UK Approval For MSD's COVID-19 Pill Molnupiravir Is A World First
The UK has led the way in granting a marketing authorization for the oral coronavirus treatment, which could help cut hospitalizations and deaths by half.